

Resource Summary Report

Generated by [kravitz2](#) on Jul 29, 2026

APC anti-human CD45

RRID:AB_2562049

Type: Antibody

Proper Citation

BioLegend Cat# 304037, RRID:AB_2562049

Antibody Information

URL: http://antibodyregistry.org/AB_2562049

Proper Citation: BioLegend Cat# 304037, RRID:AB_2562049

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_2562049

Vendor: BioLegend

Catalog Number: 304037

Alternative Catalog Numbers: 304012, 304011

Record Creation Time: 20250819T235544+0000

Record Last Update: 20250820T065108+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD45.

No alerts have been found for APC anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Kurochkin I, et al. (2026) A combinatorial transcription factor screening platform for immune cell reprogramming. *Cell systems*, 101457.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. *Cell*, 188(25), 7291.

Gao M, et al. (2025) SUCLG1 deficiency-induced histone succinylation impairs oncogene expression in acute myeloid leukemia. *Cell reports*, 44(8), 116147.

Chen H, et al. (2025) Postprandial parasympathetic signals promote lung type 2 immunity. *Neuron*, 113(5), 670.

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. *Cancer cell*, 43(4), 757.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Zhu Q, et al. (2025) Procr+ chondroprogenitors sense mechanical stimuli to govern articular cartilage maintenance and regeneration. *Cell*.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Hamilton I, et al. (2023) Utilizing primary HLA-G+ extravillous trophoblasts and HLA-G+ EVT-like cell lines to study maternal-fetal interactions. *STAR protocols*, 4(2), 102276.

Martin-Rufino JD, et al. (2023) Massively parallel base editing to map variant effects in human hematopoiesis. *Cell*, 186(11), 2456.

Liu X, et al. (2022) CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. *Cancer cell*, 40(11), 1341.

Delgado-Gonzalez A, et al. (2022) Measuring trogocytosis between ovarian tumor and natural killer cells. *STAR protocols*, 3(2), 101425.

Wang M, et al. (2022) Acquired semi-squamization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. *Cancer cell*, 40(9), 1044.

Gonzalez VD, et al. (2021) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. *Cell reports*, 36(9), 109632.

Subedi A, et al. (2021) Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. *Cell stem cell*, 28(10), 1851.

Salvany-Celades M, et al. (2019) Three Types of Functional Regulatory T Cells Control T Cell Responses at the Human Maternal-Fetal Interface. *Cell reports*, 27(9), 2537.